{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T18:44:33Z","timestamp":1791225873647,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T00:00:00Z","timestamp":1677110400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T00:00:00Z","timestamp":1677110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 DA 043409-04S1"],"award-info":[{"award-number":["R01 DA 043409-04S1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>In sub-Saharan Africa many people who inject drugs (PWID) are living with undiagnosed or untreated HIV and experience high levels of poverty and conditions that can contribute to worse outcomes from SARS-CoV-2 infection. Identifying the burden of SARS-CoV-2 infection in marginalized populations like PWID may contribute to controlling the pandemic.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This is a nested cross-sectional study within an ongoing cohort study that recruits PWID living with HIV and their injecting and\/or sexual partners at needle and syringe program sites and methadone clinics in Kenya. Blood samples were collected from consenting participants at enrollment to determine SARS-CoV-2 antibodies using a Platellia BioRad SARS-CoV-2 total antibody enzyme-linked immunosorbent assay. Baseline data were collected on HIV status, antiretroviral therapy and methadone adherence. We used logistic regression to identify factors associated with antibody positivity and descriptive statistics to report SARS-CoV-2 antibody prevalence.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>One\u00a0thousand participants were enrolled between April and July 2021, of whom 323 (32.3%) were women and 677 (67.7%) were men. Median age of participants was 36\u00a0years (interquartile range: 30, 42). SARS-CoV-2 antibody positivity was found in 309 (30.9%) participants. Disruption in obtaining methadone service was reported by 106 (24.3%) of the participants. Men were significantly less likely than women to have SARS-CoV-2 antibodies (adjusted odds ratio [aOR]\u2009=\u20090.68, 95% confidence interval [CI] 0.51, 0.95; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01) Participants who reported a sexual or injecting partner diagnosed with SARS-CoV-2 were twofold more likely to have SARS-CoV-2 antibodies detected (aOR\u2009=\u20092.21, 95% CI 1.06, 4.58; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.032). Living with HIV was\u00a0not associated with presence of SARS-CoV-2 antibodies.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The seroprevalence of SARS-CoV-2 of 30.9% in this cohort suggests high transmission rates within this population. SARS-CoV-2 seroprevalence was similar for people living with and without HIV. A large portion of this population was noted to have had disruption in access to harm reduction services.\n<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12954-023-00754-5","type":"journal-article","created":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T06:56:02Z","timestamp":1677135362000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["SARS-CoV-2 antibody prevalence, correlates, and access to harm reduction services among people who inject drugs living with and without HIV and their partners in Kenya"],"prefix":"10.1186","volume":"20","author":[{"given":"Shradha","family":"Doshi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanley","family":"Kingston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley S.","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavna H.","family":"Chohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betsy","family":"Sambai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon L.","family":"Guthrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliza","family":"Monroe-Wise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loice W.","family":"Mbogo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Masyuko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khai Hoan","family":"Tram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Sinkele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Macharia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Bukusi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua T.","family":"Herbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carey","family":"Farquhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,23]]},"reference":[{"key":"754_CR1","doi-asserted-by":"publisher","first-page":"103127","DOI":"10.1016\/j.drugpo.2021.103127","volume":"92","author":"C Zolopa","year":"2021","unstructured":"Zolopa C, Hoj S, Bruneau J, Meeson JS, Minoyan N, Raynault MF, et al. A rapid review of the impacts of \u201cBig Events \u201d on risks, harms, and service delivery among people who use drugs: implications for responding to COVID-19. Int J Drug Policy. 2021;92:103127.","journal-title":"Int J Drug Policy"},{"key":"754_CR2","unstructured":"Kenya: WHO Coronavirus Disease (COVID-19) Dashboard. Available from: https:\/\/covid19.who.int"},{"issue":"1","key":"754_CR3","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41380-020-00880-7","volume":"26","author":"QQ Wang","year":"2021","unstructured":"Wang QQ, Kaelber DC, Xu R, Volkow ND. COVID-19 risk and outcomes in patients with substance use disorders: analyses from electronic health records in the United States. Mol Psychiatry. 2021;26(1):30\u20139.","journal-title":"Mol Psychiatry"},{"issue":"2","key":"754_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamanetworkopen.2020.37069","volume":"4","author":"JM Tesoriero","year":"2021","unstructured":"Tesoriero JM, Swain CAE, Pierce JL, Zamboni L, Wu M, Holtgrave DR, et al. COVID-19 Outcomes among Persons Living with or without Diagnosed HIV Infection in New York State. JAMA Netw Open. 2021;4(2):1\u201314.","journal-title":"JAMA Netw Open"},{"key":"754_CR5","doi-asserted-by":"crossref","unstructured":"Jassat W, Cohen C, Tempia S, Masha M, Goldstein S, Kufa T, et al. COVID-19 In-hospital mortality in South Africa: the intersection of communicable and non-communicable chronic diseases in a high HIV prevalence setting. SSRN Electr J. 2021.","DOI":"10.2139\/ssrn.3783089"},{"issue":"4","key":"754_CR6","doi-asserted-by":"publisher","first-page":"F1","DOI":"10.1097\/QAD.0000000000002836","volume":"35","author":"MM Mellor","year":"2021","unstructured":"Mellor MM, Bast AC, Jones NR, Roberts NW, Ord\u00f3\u00f1ez-Mena JM, Reith AJM, et al. Risk of adverse coronavirus disease 2019 outcomes for people living with HIV. AIDS. 2021;35(4):F1-10.","journal-title":"AIDS"},{"issue":"1","key":"754_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4102\/sajhivmed.v22i1.1220","volume":"22","author":"TI Hariyanto","year":"2021","unstructured":"Hariyanto TI, Rosalind J, Christian K, Kurniawan A. Human immunodeficiency virus and mortality from coronavirus disease 2019: a systematic review and meta-analysis. South Afr J HIV Med. 2021;22(1):1\u20137.","journal-title":"South Afr J HIV Med"},{"issue":"8","key":"754_CR8","doi-asserted-by":"publisher","first-page":"e554","DOI":"10.1016\/S2352-3018(20)30164-8","volume":"7","author":"P Vizcarra","year":"2020","unstructured":"Vizcarra P, P\u00e9rez-El\u00edas MJ, Quereda C, Moreno A, Vivancos MJ, Dronda F, et al. Description of COVID-19 in HIV-infected individuals: a single-centre, prospective cohort. Lancet HIV. 2020;7(8):e554\u201364.","journal-title":"Lancet HIV"},{"issue":"11","key":"754_CR9","doi-asserted-by":"publisher","first-page":"2933","DOI":"10.1093\/cid\/ciaa880","volume":"71","author":"K Sigel","year":"2020","unstructured":"Sigel K, Swartz T, Golden E, Paranjpe I, Somani S, Richter F, et al. Coronavirus 2019 and people living with human immunodeficiency virus: Outcomes for hospitalized patients in New York City. Clin Infect Dis. 2020;71(11):2933\u20138.","journal-title":"Clin Infect Dis"},{"key":"754_CR10","unstructured":"Boulle AA, Davies M ann, Hussey H, Morden E, Vundle Z, Zweigenthal V, et al. Risk factors for COVID-19 death in a population cohort study from the Western Cape Province, South Africa | Clinical Infectious Diseases | Oxford Academic. In: Clinical Infectious Diseases. 2020;1\u201331."},{"issue":"7","key":"754_CR11","doi-asserted-by":"publisher","first-page":"e1964","DOI":"10.1093\/cid\/ciaa1339","volume":"73","author":"D Dandachi","year":"2021","unstructured":"Dandachi D, Geiger G, Montgomery MW, Karmen-Tuohy S, Golzy M, Antar AAR, et al. Characteristics, comorbidities, and outcomes in a multicenter registry of patients with human immunodeficiency virus and coronavirus disease 2019. Clin Infect Dis. 2021;73(7):e1964\u201372.","journal-title":"Clin Infect Dis"},{"key":"754_CR12","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/hiv.13037","volume":"22","author":"C Hoffmann","year":"2021","unstructured":"Hoffmann C, Casado JL, H\u00e4rter G, Vizcarra P, Moreno A, Cattaneo D, et al. Immune deficiency is a risk factor for severe COVID-19 in people living with HIV. HIV Med. 2021;22:372\u20138.","journal-title":"HIV Med"},{"issue":"4","key":"754_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bmjopen-2020-041083","volume":"11","author":"A Monroe-Wise","year":"2021","unstructured":"Monroe-Wise A, Mbogo L, Guthrie B, Bukusi D, Sambai B, Chohan B, et al. Peer-mediated HIV assisted partner services to identify and link to care HIV-positive and HCV-positive people who inject drugs: a cohort study protocol. BMJ Open. 2021;11(4):1\u201310.","journal-title":"BMJ Open"},{"issue":"2","key":"754_CR14","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1002\/jmv.26303","volume":"93","author":"M Tr\u00e9-Hardy","year":"2021","unstructured":"Tr\u00e9-Hardy M, Wilmet A, Beukinga I, Favresse J, Dogn\u00e9 JM, Douxfils J, et al. Analytical and clinical validation of an ELISA for specific SARS-CoV-2 IgG, IgA, and IgM antibodies. J Med Virol. 2021;93(2):803\u201311.","journal-title":"J Med Virol"},{"issue":"6524","key":"754_CR15","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1126\/science.abe1916","volume":"371","author":"S Uyoga","year":"2021","unstructured":"Uyoga S, Adetifa IMO, Karanja HK, Nyagwange J, Tuju J, Wanjiku P, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Kenyan blood donors. Science. 2021;371(6524):79\u201382.","journal-title":"Science"},{"issue":"1","key":"754_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-021-24062-3","volume":"12","author":"IMO Adetifa","year":"2021","unstructured":"Adetifa IMO, Uyoga S, Gitonga JN, Mugo D, Otiende M, Nyagwange J, et al. Temporal trends of SARS-CoV-2 seroprevalence during the first wave of the COVID-19 epidemic in Kenya. Nat Commun. 2021;12(1):1\u20136.","journal-title":"Nat Commun"},{"key":"754_CR17","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ijid.2021.08.062","volume":"112","author":"I Ngere","year":"2021","unstructured":"Ngere I, Dawa J, Hunsperger E, Otieno N, Masika M, Amoth P, et al. High seroprevalence of SARS-CoV-2 but low infection fatality ratio eight months after introduction in Nairobi Kenya. Int J Infect Dis. 2021;112:25\u201334.","journal-title":"Int J Infect Dis"},{"issue":"14","key":"754_CR18","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1097\/QAD.0000000000003054","volume":"35","author":"TA Crowell","year":"2021","unstructured":"Crowell TA, Daud II, Maswai J, Owuoth J, Singoei V, Imbach M, et al. Severe acute respiratory syndrome coronavirus-2 antibody prevalence in people with and without HIV in rural Western Kenya, January to March. AIDS. 2021;35(14):2401\u20134.","journal-title":"AIDS"},{"issue":"1","key":"754_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12954-021-00499-z","volume":"18","author":"K Lindqvist","year":"2021","unstructured":"Lindqvist K, Wallmofeldt C, Holm\u00e9n E, Hammarberg A, K\u00e5berg M. Health literacy and changes in pattern of drug use among participants at the Stockholm Needle Exchange Program during the COVID-19 pandemic. Harm Reduct J. 2021;18(1):1\u201314.","journal-title":"Harm Reduct J"},{"issue":"6570","key":"754_CR20","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1126\/science.abk0414","volume":"374","author":"SPC Brand","year":"2021","unstructured":"Brand SPC, Ojal J, Aziza R, Were V, Okiro EA, Kombe IK, et al. COVID-19 transmission dynamics underlying epidemic waves in Kenya. Science. 2021;374(6570):989\u201394.","journal-title":"Science"},{"key":"754_CR21","doi-asserted-by":"crossref","unstructured":"Lucinde R, Mugo D, Bottomley C, Aziza R, Gitonga J, Karanja H, et al. Sero-surveillance for IgG to SARS-CoV-2 at antenatal care clinics in two Kenyan referral hospitals Corresponding author + Contributed equally KEMRI-Wellcome Trust Research Programme. medRxiv. 2021;2021.02.05.21250735.","DOI":"10.1101\/2021.02.05.21250735"},{"key":"754_CR22","doi-asserted-by":"publisher","first-page":"127","DOI":"10.12688\/wellcomeopenres.16748.1","volume":"6","author":"J Ojal","year":"2021","unstructured":"Ojal J, Brand SPC, Were V, Okiro EA, Kombe IK, Mburu C, et al. Revealing the extent of the first wave of the COVID-19 pandemic in Kenya based on serological and PCR-test data. Wellcome Open Res. 2021;6:127.","journal-title":"Wellcome Open Res"},{"key":"754_CR23","unstructured":"Kilifi KWTRP. Status of the COVID-19 pandemic in Kenya: Evidence from national case-based surveillance, serosurveillance and hospital-based clinical surveillance KEY MESSAGES. 2020;(October)."},{"key":"754_CR24","unstructured":"Bertagnolio S, Thwin SS, Silva R, Ford N, Baggaley R, Vitoria M, et al. Clinical features and prognostic factors of COVID-19 in people living with HIV hospitalized with suspected or confirmed SARS-CoV-2 infection. 11th IAS Conference on HIV Science. 2021;(July):abstract PEBLB20."},{"issue":"4","key":"754_CR25","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/dar.13079","volume":"39","author":"PM Dietze","year":"2020","unstructured":"Dietze PM, Peacock A. Illicit drug use and harms in Australia in the context of COVID-19 and associated restrictions: anticipated consequences and initial responses. Drug Alcohol Rev. 2020;39(4):297\u2013300.","journal-title":"Drug Alcohol Rev"},{"key":"754_CR26","doi-asserted-by":"publisher","first-page":"102872","DOI":"10.1016\/j.drugpo.2020.102872","volume":"83","author":"AB Collins","year":"2020","unstructured":"Collins AB, Ndoye CD, Arene-Morley D, Marshall BDL. Addressing co-occurring public health emergencies: the importance of naloxone distribution in the era of COVID-19. Int J Drug Policy. 2020;83:102872.","journal-title":"Int J Drug Policy"},{"issue":"6","key":"754_CR27","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1007\/s11524-020-00484-0","volume":"97","author":"N Glober","year":"2020","unstructured":"Glober N, Mohler G, Huynh P, Arkins T, O\u2019Donnell D, Carter J, et al. Impact of COVID-19 pandemic on drug overdoses in Indianapolis. J Urban Health. 2020;97(6):802\u20137.","journal-title":"J Urban Health"},{"issue":"5","key":"754_CR28","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/1753-6405.12810","volume":"42","author":"ML Giles","year":"2018","unstructured":"Giles ML, Hickman J, Lingam V, Buttery J. Results from a mobile outreach influenza vaccination program for vulnerable and high-risk populations in a high-income setting: lessons learned. Aust N Z J Public Health. 2018;42(5):447\u201350.","journal-title":"Aust N Z J Public Health"},{"issue":"3","key":"754_CR29","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.drugpo.2014.01.009","volume":"25","author":"N Walsh","year":"2014","unstructured":"Walsh N, Verster A, Rodolph M, Akl EA. WHO guidance on the prevention of viral hepatitis B and C among people who inject drugs. Int J Drug Policy. 2014;25(3):363\u201371.","journal-title":"Int J Drug Policy"},{"issue":"1","key":"754_CR30","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1093\/jurban\/jti016","volume":"82","author":"FL Altice","year":"2005","unstructured":"Altice FL, Bruce RD, Walton MR, Buitrago MI. Adherence to hepatitis B virus vaccination at syringe exchange sites. J Urban Health. 2005;82(1):151\u201361.","journal-title":"J Urban Health"},{"issue":"1","key":"754_CR31","first-page":"9","volume":"27","author":"S Friedman","year":"2006","unstructured":"Friedman S, Rossi D, Flom PL. \u201cBig events\u201d and networks. Connect (Tor). 2006;27(1):9\u201314.","journal-title":"Connect (Tor)"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-023-00754-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-023-00754-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-023-00754-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T08:18:54Z","timestamp":1700468334000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-023-00754-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,23]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["754"],"URL":"https:\/\/doi.org\/10.1186\/s12954-023-00754-5","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,23]]},"assertion":[{"value":"26 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study received ethical approval from the University of Washington Institutional Review Board and the Kenyatta National Hospital-University of Nairobi Ethics and Research Committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"This is a nested cross-sectional study within an ongoing prospective cohort study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Study design"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21"}}